BusinessPhoto: Business StandardMankind Pharma Q2 PAT Rises 37.7% on Strong Domestic Chronic Drug Demand
Mankind Pharma reported a 37.7% year-on-year rise in consolidated net profit for Q2 FY27, reaching ₹716 crore compared to ₹520 crore last year. Revenue grew 17.3% to ₹4,338 crore, driven mainly by domestic chronic drug demand. The India business grew 14.8% to ₹3,657 crore, with strong sales in cardiac and anti-diabetes therapies. OTC consumer healthcare growth was muted at 1.2%.
Business Standard··Delhi

